Moloney Securities Asset Management’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-4,852
Closed -$839K 429
2021
Q4
$839K Hold
4,852
0.14% 176
2021
Q3
$705K Hold
4,852
0.13% 199
2021
Q2
$640K Hold
4,852
0.12% 211
2021
Q1
$623K Sell
4,852
-276
-5% -$34K 0.12% 202
2020
Q4
$611K Sell
5,128
-80
-2% -$9.75K 0.14% 178
2020
Q3
$596K Buy
5,208
+638
+14% +$75.4K 0.16% 149
2020
Q2
$521K Buy
4,570
+325
+8% +$34.5K 0.15% 151
2020
Q1
$341K Sell
4,245
-900
-17% -$93.2K 0.12% 171
2019
Q4
$549K Sell
5,145
-25
-0.5% -$2.61K 0.17% 154
2019
Q3
$553K Sell
5,170
-658
-11% -$67.5K 0.18% 139
2019
Q2
$593K Buy
5,828
+658
+13% +$63.2K 0.2% 137
2019
Q1
$465K Hold
5,170
0.16% 166
2018
Q4
$431K Hold
5,170
0.18% 156
2018
Q3
$558K Hold
5,170
0.19% 143
2018
Q2
$568K Hold
5,170
0.22% 141
2018
Q1
$519K Sell
5,170
-250
-5% -$25.6K 0.21% 140
2017
Q4
$534K Hold
5,420
0.22% 130
2017
Q3
$508K Hold
5,420
0.23% 130
2017
Q2
$602K Hold
5,420
0.3% 104
2017
Q1
$532K Hold
5,420
0.28% 122
2016
Q4
$498K Buy
+5,420
New +$467K 0.3% 109

Other funds holding DGX

Moloney Securities Asset Management's DGX Position: Q1 2022 in Review

Moloney Securities Asset Management sold out of Quest Diagnostics (DGX) in Q1 2022, closing a stake of 4,852 shares — an estimated $839K sold.

Moloney Securities Asset Management first reported a position in DGX in Q4 2016 and held it in 21 quarters. The position peaked at $839K in Q4 2021. 851 funds tracked by Wall St. Rank hold DGX as of Q1 2022.

  • Moloney Securities Asset Management reported no remaining Quest Diagnostics position as of Q1 2022 after selling out during the quarter.
  • Moloney Securities Asset Management sold 4,852 Quest Diagnostics shares in Q1 2022, an estimated $839K.
  • Moloney Securities Asset Management first reported a position in Quest Diagnostics in Q4 2016 and held it in 21 quarters.
  • Moloney Securities Asset Management's Quest Diagnostics position peaked at $839K in Q4 2021.
  • 851 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2022.

Based on Moloney Securities Asset Management's 13F filing for Q1 2022, filed 10 May 2022.